The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. Alaunos engages in the development of adoptive TCR engineered T-cell therapies designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs.
Cyborg Score Rationale
Early-stage clinical pipeline with promising preclinical obesity data and TCR-T cell platform, but minimal revenue and high cash burn typical of pre-revenue biotech. Recent ALN1003 data shows therapeutic potential but company remains entirely dependent on successful clinical advancement.
Top Insights
Lead obesity candidate ALN1003 showed promising results in diet-induced obesity mouse studies with mean body weight loss of up to -12.9%
Stock volatility decreased from 18% to 12% over the past year but remains higher than 75% of US stocks
Company develops hunTR TCR discovery platform to target driver mutations in oncology
Dual pipeline approach diversifies risk across metabolic and oncology markets, each representing multi-billion dollar opportunities